

Maryam Foroozesh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2360074/publications.pdf>

Version: 2024-02-01

40
papers

985
citations

471509
17
h-index

434195
31
g-index

40
all docs

40
docs citations

40
times ranked

1222
citing authors

#	ARTICLE	IF	CITATIONS
1	Student Grade Evaluation, Survey Feedback, and Lessons Learned during the COVID-19 Pandemic: A Comparative Study of Virtual vs. In-Person Offering of a Freshman-Level General Chemistry II Course in Summer at Xavier University of Louisiana. <i>Education Sciences</i> , 2022, 12, 226.	2.6	4
2	Identification of CYP 2A6 inhibitors in an effort to mitigate the harmful effects of the phytochemical nicotine. , 2021, 7, .		2
3	Acute toxicity evaluation of a novel ceramide analog for the treatment of breast cancer. <i>Toxicology Reports</i> , 2021, 8, 1521-1526.	3.3	3
4	Developing new ceramide analogs and identifying novel sphingolipid-controlled genes against a virus-associated lymphoma. <i>Blood</i> , 2020, 136, 2175-2187.	1.4	4
5	BUILDING INTEGRATED PATHWAYS TO INDEPENDENCE FOR DIVERSE BIOMEDICAL RESEARCHERS: PROJECT PATHWAYS. , 2020, 2020, 483-485.		0
6	Transactivation of human endogenous retroviruses by tumor viruses and their functions in virus-associated malignancies. <i>Oncogenesis</i> , 2019, 8, 6.	4.9	46
7	Coumarins and P450s, Studies Reported to-Date. <i>Molecules</i> , 2019, 24, 1620.	3.8	32
8	All for One and One for All: Coordinating the Resources of Individual Student Research Training Initiatives in Biomedical Sciences at Xavier University of Louisiana. <i>Diversity in Higher Education</i> , 2019, 22, 129-149.	0.1	0
9	The sphingosine kinase 2 inhibitor ABC294640 displays anti- ϵ -small cell lung cancer activities <i>in vitro</i> and <i>in vivo</i> . <i>International Journal of Cancer</i> , 2018, 142, 2153-2162.	5.1	35
10	Inhibition of breast tumor growth in mice after treatment with ceramide analog 315. <i>Anti-Cancer Drugs</i> , 2018, 29, 898-903.	1.4	4
11	Ethyl 2-[2-(4-oxo-4H-chromen-2-yl)phenoxy]acetate. <i>IUCrData</i> , 2018, 3, .	0.3	2
12	A dibenzofuran derivative: 2-(pentyloxy)dibenzo[b,d]furan. <i>IUCrData</i> , 2018, 3, .	0.3	2
13	DESIGN AND SYNTHESIS OF DIBENZYLURAN BASED ETHER AND ESTER DERIVATIVES AS POTENTIAL P450 INHIBITORS. <i>Journal of Undergraduate Chemistry Research</i> , 2018, 17, 102-104.	0.5	0
14	Review of Ligand Specificity Factors for CYP1A Subfamily Enzymes from Molecular Modeling Studies Reported to-Date. <i>Molecules</i> , 2017, 22, 1143.	3.8	44
15	Building integrated pathways to independence for diverse biomedical researchers: Project Pathways, the BUILD program at Xavier University of Louisiana. <i>BMC Proceedings</i> , 2017, 11, 28.	1.6	9
16	Ortho-Methylarylamines as Time-Dependent Inhibitors of Cytochrome P450 1A1 Enzyme. <i>Drug Metabolism Letters</i> , 2017, 10, 270-277.	0.8	6
17	OPTIMIZATION OF SCALE-UP SYNTHESIS OF ANTI-CANCER CERAMIDE ANALOG 315. <i>Journal of Undergraduate Chemistry Research</i> , 2017, 16, 89-90.	0.5	2
18	Novel functionalized 5-(phenoxyethyl)-1,3-dioxane analogs exhibiting cytochrome P450 inhibition: a patent evaluation WO2015048311 (A1). <i>Expert Opinion on Therapeutic Patents</i> , 2016, 26, 139-147.	5.0	2

#	ARTICLE	IF	CITATIONS
19	A Ligand-Based Drug Design. Discovery of 4-Trifluoromethyl-7,8-pyrano-coumarin as a Selective Inhibitor of Human Cytochrome P450 1A2. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 6481-6493.	6.4	27
20	3-Ketone-4,6-diene ceramide analogs exclusively induce apoptosis in chemo-resistant cancer cells. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 1412-1420.	3.0	13
21	Ethynylflavones, Highly Potent, and Selective Inhibitors of Cytochrome P450 1A1. <i>Chemical Research in Toxicology</i> , 2014, 27, 1431-1439.	3.3	6
22	Cytochrome P450 Family 1 Inhibitors and Structure-Activity Relationships. <i>Molecules</i> , 2013, 18, 14470-14495.	3.8	84
23	A review of ceramide analogs as potential anticancer agents. <i>Future Medicinal Chemistry</i> , 2013, 5, 1405-1421.	2.3	48
24	Pyranoflavones: A Group of Small-Molecule Probes for Exploring the Active Site Cavities of Cytochrome P450 Enzymes 1A1, 1A2, and 1B1. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 4082-4092.	6.4	38
25	Development of Flavone Propargyl Ethers as Potent and Selective Inhibitors of Cytochrome P450 Enzymes 1A1 and 1A2. <i>Drug Metabolism Letters</i> , 2013, 6, 275-284.	0.8	19
26	DESIGN, SYNTHESIS, AND EVALUATION OF A FAMILY OF PROPARGYL PYRIDINYL ETHERS AS POTENTIAL CYTOCHROME P450 INHIBITORS. <i>Journal of Undergraduate Chemistry Research</i> , 2013, 12, 91-94.	0.5	2
27	DESIGN, SYNTHESIS, AND EVALUATION OF CARBAZOLE ANALOGS AS POTENTIAL CYTOCHROME P450 INHIBITORS. <i>Journal of Undergraduate Chemistry Research</i> , 2013, 12, 92-95.	0.5	1
28	Inhibition of Cytochrome P450 Enzymes by Quinones and Anthraquinones. <i>Chemical Research in Toxicology</i> , 2012, 25, 357-365.	3.3	44
29	7-Ethynylcoumarins: Selective Inhibitors of Human Cytochrome P450s 1A1 and 1A2. <i>Chemical Research in Toxicology</i> , 2012, 25, 1047-1057.	3.3	24
30	Insights on Cytochrome P450 Enzymes and Inhibitors Obtained Through QSAR Studies. <i>Molecules</i> , 2012, 17, 9283-9305.	3.8	43
31	Novel d-erythro N-octanoyl sphingosine analogs as chemo- and endocrine-resistant breast cancer therapeutics. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 1191-1195.	2.3	26
32	Novel anti-viability ceramide analogs: Design, synthesis, and structure-activity relationship studies of substituted (S)-2-(benzylideneamino)-3-hydroxy-N-tetradecylpropanamides. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 5316-5322.	3.0	15
33	In Silico Studies of Polyaromatic Hydrocarbon Inhibitors of Cytochrome P450 Enzymes 1A1, 1A2, 2A6, and 2B1. <i>Chemical Research in Toxicology</i> , 2010, 23, 600-607.	3.3	28
34	Design, Synthesis, and Biological Activity of a Family of Novel Ceramide Analogues in Chemoresistant Breast Cancer Cells. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 5748-5752.	6.4	37
35	Benzoate Esters as Potential Apoptotic Agents. <i>FASEB Journal</i> , 2009, 23, 534.3.	0.5	0
36	Methoxyflavone Inhibitors of Cytochrome P450. <i>Journal of Chemical Crystallography</i> , 2008, 38, 231-237.	1.1	9

#	ARTICLE	IF	CITATIONS
37	Differential Inhibition of Cytochromes P450 3A4 and 3A5 by the Newly Synthesized Coumarin Derivatives 7-Coumarin Propargyl Ether and 7-(4-Trifluoromethyl)coumarin Propargyl Ether. <i>Drug Metabolism and Disposition</i> , 2008, 36, 2234-2243.	3.3	13
38	Naphthoflavone propargyl ether inhibitors of cytochrome P450. <i>Journal of Chemical Crystallography</i> , 2006, 36, 289-296.	1.1	6
39	Selectivity of Polycyclic Inhibitors for Human Cytochrome P450s 1A1, 1A2, and 1B1. <i>Chemical Research in Toxicology</i> , 1998, 11, 1048-1056.	3.3	198
40	Aryl Acetylenes as Mechanism-Based Inhibitors of Cytochrome P450-Dependent Monooxygenase Enzymes. <i>Chemical Research in Toxicology</i> , 1997, 10, 91-102.	3.3	107